Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Memo of Telecon - Cervarix, June 20, 2007

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Biologics Evaluation and Research




Date:               June 20, 2007
To:                  STN BL125259.0
From:             Rebecca Olin, CBER/OCBQ/DMPQ/MRBII
Subject:          Memo of Telecon



On June 20, 2007, 3 pm EST, I telephoned Linda Kramer, Manager US Regulatory Affairs, to inform her of the DMPQ/OVRR decision regarding their request that they be allowed to use the data generated for Cervarix lot #---b(4)---------- in support of the process validation.  This lot had been filled on filling line -b(4)- located in Rixensart which will no longer be used for the Cervarix product.  I informed her that after discussions with Laurie Norwood, Dr. Chiang Syin, and BLA Chairperson Dr. Gopa Raychaudhuri that there were no objections to the data being used in support of the process validation for Cervarix.  I also instructed her to submit a letter as an Amendment to the BLA stating the line would no longer be used for Cervarix.  Ms. Kramer agreed to do so.  I also told her that since the removal of -b(4)-  was noted in the Kinrix BLA that no further action would be required for that file.  The conversation ended at approximately 3:15 pm.


Page Last Updated: 04/14/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English